Home

Growth Equity Opportunities Fund IV, LLC

CIK 1644965 · last filed 2022-10-21

Growth Equity Opportunities Fund IV, LLC is a corporate insider who has filed 10 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for AVEO, was dated Oct 21, 2022. Across all open-market trades the lifetime net is +$65.5M, making them a net buyer over the disclosed history. The firm reports its address in Timonium, MD. 24 SEC filings were submitted jointly with NEA 15 GP, LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

10

Lifetime Open-Market Net

$65.53M

Filer Profile

Reported Address
1954 GREENSPRING DRIVE
SUITE 600
TIMONIUM, MD 21093
Phone
(410) 842-4000
State of Incorporation
DE
Formerly Known As
Growth Equity Opportunities IV, LLC (2015–2018)
Related Filers
NEA 15 GP, LLC — 24 joint filings, latest 2020-06-22
NEA Partners 15, L.P. — 24 joint filings, latest 2020-06-22
New Enterprise Associates 15, L.P. — 24 joint filings, latest 2020-06-22
NEA 14 GP, LTD — same reported address
NEA 17 GP, LLC — same reported address
NEA Partners 14, L.P. — same reported address
NEA Partners 17, L.P. — same reported address
New Enterprise Associates 14, L.P. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AVEO PHARMACEUTICALS, INC. (AVEO) Delisted 10%+ Owner 0 $15.00 $0 $41.46M 6 2022-10-21
Oruka Therapeutics, Inc. (ABIO) Delisted 10%+ Owner 0 $28.80 $0 -$2.93M 1 2018-02-27
Cascadian Therapeutics, Inc. (CASC) Delisted 10%+ Owner 10,882,574 — — $0 1 2018-02-22
Achaogen, Inc. (AKAO) Delisted 10%+ Owner 5,215,128 — — $27.00M 1 2016-12-19

Recent Filings

10 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-10-21 AVEO PHARMACEUTICALS, INC. (AVEO) Delisted Other (J) −3,952,957 $0 EDGAR
2019-04-08 AVEO PHARMACEUTICALS, INC. (AVEO) Delisted Buy (P) +17,391,308 $19.83M EDGAR
2018-08-22 AVEO PHARMACEUTICALS, INC. (AVEO) Delisted Buy (P) +2,654,864 $6.00M EDGAR
2018-06-28 AVEO PHARMACEUTICALS, INC. (AVEO) Delisted Buy (P) +769,700 $1.62M EDGAR
2018-05-21 AVEO PHARMACEUTICALS, INC. (AVEO) Delisted Buy (P) +945,916 $2.01M EDGAR
2018-03-13 — U −43,530,296 $0
2018-02-27 Oruka Therapeutics, Inc. (ABIO) Delisted Sell (S) −5,840,836 -$2.93M EDGAR
2018-02-22 Cascadian Therapeutics, Inc. (CASC) Delisted Conv (C) +7,272,000 $24.00M EDGAR
2017-03-29 AVEO PHARMACEUTICALS, INC. (AVEO) Delisted Buy (P) +24,000,000 $12.00M EDGAR
2016-12-19 Achaogen, Inc. (AKAO) Delisted Buy (P) +2,000,000 $27.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.